KR101355121B1 - 캄토테신의 입체선택적 방법 및 결정성 형태 - Google Patents

캄토테신의 입체선택적 방법 및 결정성 형태 Download PDF

Info

Publication number
KR101355121B1
KR101355121B1 KR1020077016814A KR20077016814A KR101355121B1 KR 101355121 B1 KR101355121 B1 KR 101355121B1 KR 1020077016814 A KR1020077016814 A KR 1020077016814A KR 20077016814 A KR20077016814 A KR 20077016814A KR 101355121 B1 KR101355121 B1 KR 101355121B1
Authority
KR
South Korea
Prior art keywords
delete delete
camptothecin
acetal
reaction
formyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077016814A
Other languages
English (en)
Korean (ko)
Other versions
KR20070097535A (ko
Inventor
파올로 까르미나띠
마리아 오르넬라 틴티
마우로 마르지
파브리지오 기오르기
월터 카브리
마르코 알페기아니
도메니코 베르가니
파올로 게티
Original Assignee
시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. filed Critical 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이.
Publication of KR20070097535A publication Critical patent/KR20070097535A/ko
Application granted granted Critical
Publication of KR101355121B1 publication Critical patent/KR101355121B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1020077016814A 2004-12-21 2005-12-16 캄토테신의 입체선택적 방법 및 결정성 형태 Expired - Fee Related KR101355121B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04030246 2004-12-21
EP04030246.5 2004-12-21
PCT/EP2005/056849 WO2006067092A2 (en) 2004-12-21 2005-12-16 Stereoselective process and crystalline forms of a camptothecin

Publications (2)

Publication Number Publication Date
KR20070097535A KR20070097535A (ko) 2007-10-04
KR101355121B1 true KR101355121B1 (ko) 2014-01-24

Family

ID=34927884

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077016814A Expired - Fee Related KR101355121B1 (ko) 2004-12-21 2005-12-16 캄토테신의 입체선택적 방법 및 결정성 형태

Country Status (18)

Country Link
US (3) US7799921B2 (enExample)
EP (1) EP1828196B1 (enExample)
JP (2) JP5491699B2 (enExample)
KR (1) KR101355121B1 (enExample)
CN (1) CN101084221B (enExample)
AU (1) AU2005318227B2 (enExample)
BR (1) BRPI0515832A (enExample)
CA (1) CA2590756C (enExample)
CY (1) CY1117243T1 (enExample)
DK (1) DK1828196T3 (enExample)
ES (1) ES2395930T3 (enExample)
HR (1) HRP20120926T1 (enExample)
ME (1) ME01495B (enExample)
PL (1) PL1828196T3 (enExample)
PT (1) PT1828196E (enExample)
RS (1) RS52585B (enExample)
SI (1) SI1828196T1 (enExample)
WO (1) WO2006067092A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828196B1 (en) * 2004-12-21 2012-10-17 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Stereoselective process and crystalline forms of a camptothecin
ITRM20050418A1 (it) * 2005-08-04 2007-02-05 Sigma Tau Ind Farmaceuti Sistemi terapeutici a rilascio immediato per il migliorato assorbimento orale di 7-[(e)-t-butilossimminometil] camptotecina.
FR2938534B1 (fr) 2008-11-14 2012-10-26 Sanofi Aventis Procede de preparation de l'hemifumarate d'eplivanserine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044977A1 (en) * 1999-03-09 2000-10-18 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03271278A (ja) * 1990-03-16 1991-12-03 Nissan Chem Ind Ltd ２―アニリノピリミジン誘導体および農園芸用殺菌剤
JP3046401B2 (ja) * 1991-06-18 2000-05-29 イハラケミカル工業株式会社 ６−〔１−（ｎ−アルコキシイミノ）エチル〕サリチル酸誘導体及びその製造法
IL106786A (en) * 1992-09-10 1997-02-18 Basf Ag Substituted pyridine derivatives and fungicidal compositions containing them
AU2003215594A1 (en) * 2002-03-01 2003-09-16 Pharmacia Italia S.P.A. Crystalline polymorphic form of irinotecan hydrochloride
EP1828196B1 (en) * 2004-12-21 2012-10-17 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Stereoselective process and crystalline forms of a camptothecin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1044977A1 (en) * 1999-03-09 2000-10-18 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
유럽 특허출원공개공보 EP1044977(2000.10.18.) *

Also Published As

Publication number Publication date
US20100311783A1 (en) 2010-12-09
HK1113487A1 (en) 2008-10-03
WO2006067092A3 (en) 2006-11-02
EP1828196A2 (en) 2007-09-05
RS52585B (sr) 2013-04-30
US7799921B2 (en) 2010-09-21
CN101084221B (zh) 2011-05-11
PL1828196T3 (pl) 2013-02-28
AU2005318227A1 (en) 2006-06-29
EP1828196B1 (en) 2012-10-17
ES2395930T3 (es) 2013-02-18
JP5982261B2 (ja) 2016-08-31
CN101084221A (zh) 2007-12-05
US8124769B2 (en) 2012-02-28
PT1828196E (pt) 2012-11-19
KR20070097535A (ko) 2007-10-04
CY1117243T1 (el) 2017-04-05
US20090239893A1 (en) 2009-09-24
JP2013067629A (ja) 2013-04-18
ME01495B (me) 2014-04-20
DK1828196T3 (da) 2012-11-26
BRPI0515832A (pt) 2008-08-05
CA2590756C (en) 2014-09-02
US20100311784A1 (en) 2010-12-09
JP5491699B2 (ja) 2014-05-14
JP2008524306A (ja) 2008-07-10
CA2590756A1 (en) 2006-06-29
WO2006067092A2 (en) 2006-06-29
HRP20120926T1 (hr) 2012-12-31
SI1828196T1 (sl) 2012-12-31
AU2005318227B2 (en) 2011-08-18
US8101758B2 (en) 2012-01-24

Similar Documents

Publication Publication Date Title
NO341812B1 (no) Camptotecinderivater med antitumoraktivitet
EP4265620A1 (en) Novel camptothecin derivative, composition containing same, and use thereof
JP2025526425A (ja) 抗体薬物複合体に適した毒素分子
WO1991018003A1 (fr) Derive antitumoral de be-13793c
US8101758B2 (en) Stereoselective process and crystalline forms of a camptothecin
DK2044080T3 (en) Camptothecin derivatives with antitumor activity
US8349863B2 (en) Crystalline polymorphic form of a camptothecin analogue
MX2007007258A (en) Stereoselective process and crystalline forms of a camptothecin
HK1113487B (en) Stereoselective process and crystalline forms of a camptothecin
PL188075B1 (pl) Rozpuszczalne w wodzie C-pierścieniowe analogi 20(S)-kamptotecyny, kompozycja farmaceutyczna zawierająca te związki, ich zastosowanie oraz sposób wytwarzania
KR101398591B1 (ko) 제암성 활성을 갖는 캠토테신 유도체
ZA200510323B (en) Benzo[B]pyrano[3,2-H]acridin-2-one cinnamate compounds, a process for their preparation and pharmaceutical compositions containing them
HK1089160B (en) 7-imino derivatives of camptothecin having antitumor activity
HK1089160A1 (zh) 具有抗肿瘤活性的喜树硷的7-亚氨基衍生物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20170111

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180105

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190108

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210118

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210118